Providing best-in-class strategic and tactical advisory to US- and European-based companies in China since 2007. Having advised over a 100+ American and European clients with regards to their China activities, Pantek leverages its long local track record and established relationships with key industry players in the Greater China region to provide its clients with unparalleled insight and access to China-based market-entry opportunities, M&A dealflow, strategic capital investment channels and cross-border joint venture opportunities coupled with seasoned local execution capabilities.
Pantek provides confidential strategic and tactical advisory services to its American and European clients related to China-targeted market entry, mergers & acquisitions, cross-border joint venture structuring and financing and related activities. The Pantek team is comprised of professionals with backgrounds in Wall St. and APAC investment banking, international venture capital and private equity, APAC-focused management consulting, hedge fund management, and line operating roles within the technology, healthcare, media and energy sectors with specific focus on the APAC markets. Pantek’s management and deal support teams are all multi-lingual and possess significant cross-cultural business experience in the US, Europe and the Greater China region.
Pantek provides its clients with China-focused strategic and tactical advisory related to identifying and qualifying strategic partnership targets, conducting required business development to facilitate discussions with the appropriate targets and key personnel within those targets, while also providing advisory related to establishing local China operations and structuring and financing of joint venture partnerships.
Pantek provides its clients with a full array of merger & acquisitions advisory services with specific emphasis on market-entry acquisitions of targets based in the Greater China region. Pantek provides unique and sophisticated cross-border insights and capabilities to its clients, both sellers and buyers, targeting the Greater China region.
Pantek provides its clients with full advisory for domestic (local RMB currency) and international (USD currency) fundraising advisory targeting investors based in the Greater China region. Pantek possesses a unique network of institutional, strategic and high-net worth investors who are active industry participants in technology, media, healthcare and energy and experience in cross-border transactions.
Pantek provides its clients who wish to sell medical devices, IVDs, drugs, and other healthcare products in China a full array of services. Pantek offers regulatory consulting, regulatory strategy, product registration, regulatory compliance, local marketing holder, local agent representation, and clinical operations.
Pantek’s principals operate in a broad array of market verticals where they have strong operating backgrounds and established networks in the Greater China region including high technology, bio-medtech, consumer packaged goods, high-end industrial goods and alternative energy.
Jack founded Pantek and leads the firm's cross-border presence in the US and China. Prior to founding Pantek, Jack was Vice President of Marketing with Symwave, a fabless analog/mixed-signal semiconductor company providing integrated circuit solutions to the consumer and digital media markets with operations in China, Taiwan and the US. Jack joined Symwave in 2004 as the first US employee and was instrumental in the early development and implementation of the company's venture financing and cross-border sales and marketing strategies. The company raised over $40M in venture capital, grew to over 70 employees and shipped multiple high-performance analog IC product lines to the leading Greater Chinese and US consumer electronic and computer manufacturers before its sale to SMSC Inc. (NASDAQ: SMSC) in 2010.
Previous to Symwave, Mr. Bell was an Associate with Mission Ventures, a $500M early- and mid-stage venture capital fund where he managed direct equity investments and provided marketing and business development support to Mission's semiconductor, hardware systems and related software and services portfolio companies.
Prior to Mission Ventures, Jack was an Equity Analyst with UBS PaineWebber in New York with UBS' Telecommunications Equipment Group, providing equity coverage and M&A advisory to public and private companies in the telecommunications systems, sub-systems and related semiconductor markets.
Jack began his career as an Analyst with the Global Partner Ventures, a $100M Moscow, Russia-based private equity fund investing in recently privatized telecommunications, manufacturing, energy and media companies in the former Soviet bloc countries where Jack advised companies leading up to, during and after the Russian financial collapse of 1998. Jack graduated with honors from Colgate University and is conversant in Russian, Portuguese and beginning Mandarin Chinese.
Mary leads the firm’s biomedical healthcare group. She has 30 years of experience in the healthcare and pharmaceutical industries.
Mary has lead teams to approvals for medical devices, drugs and healthcare products worldwide regions including Greater China (PRC, Hong Kong, Taiwan, Macau), Southeast Asia (Vietnam, Philippines, Thailand, Singapore), Russia and the CIS States and Latin America. She has managed people directly and in virtual environments, in consulting teams, business partnerships, and global affiliations. Her leadership skills and regulatory/quality experience positions her strategically between the client and the local affiliate.
Prior to Pantek, Mary was the Senior Vice President of Regulatory Affairs and Quality Assurance for Evofem, Inc. and WomanCare Global. Mary has worked for international commercial companies and nonprofit organization that provide healthcare technologies around the world. Previously, Mary was a President and Principal Consultant of Jarosz Regulatory Services and was responsible for regulatory strategy, submissions, and post-approval activities for drugs worldwide and provided expertise small, medium, and multi-national pharmaceutical companies. Prior to founding Jarosz Regulatory Services, Mary worked in the pharmaceutical industry in product development and in international regulatory affairs. She has focused her expertise in the international arena since 1991. Mary also has a considerable clinical background acquired during practice as a pharmacist and clinical instructor in an academic hospital setting and has been in health care since 1984. She has received a bachelor’s degree in Pharmacy from the University of Illinois at Chicago, is a Registered Pharmacist, and an active member of RAPS, DIA, and a Fellow of the European organization, TOPRA (FTOPRA).
Gary leads the firm’s retail group. He has 30 years of experience working in specialty retail and also extensive international experience.
Gary is a bottom-line oriented senior business executive with a unique blend of skills and accomplishments in general management, finance, business development, and operations with an emphasis on specialty retail. He has substantial international business experience having worked in 28 countries and lived in the UK, Switzerland, and Japan. Gary has a proven track record of success in growing companies from start up to $250M in revenue, driving business growth and value, including expertise financing in private markets, both equity and debt.
Prior to Pantek, Gary was the Financial and Business Director for AdLens where he opened the company’s first wholly owned distribution company in Japan, recruited the current CEO and implemented and managed distribution. Also with Adlens, he negotiated full product global joint venture and / or distribution agreements in Russia, Europe and Mexico; and worked with management to obtain product governmental registration in the USA and Russia.
Previous to AdLens, Gary teamed up with the founder of Lenscrafters and took the one-hour optical superstore retailing concept to Europe where he built a profitable business with over 200 stores operating in 16 countries and £170M ($255M ) in sales. As Chief Operating Officer, Gary was responsible for opening 90 optical retail stores in 11 countries in 7 different languages with operational responsibility for all aspects of the business. He accelerated geographical expansion by introducing and managing a 50 store joint venture / franchise initiative resulting in a profitable franchise operation in 3 years.
Dr. Li leads Pantek's Healthcare practice. Dr. Li brings over 20 years of experience in international biotechnology, pharmaceutical and medical research services as well as a strong background in international private client wealth management services servicing investors active in the biotechnology sector and cross-border mergers & acquisitions between US and Chinese companies.
Throughout his career, Richard has served as a trusted advisor to US and Chinese companies in the biomedical, CRO and advanced materials sectors, assisting these companies with market entry, joint venture partnerships and mergers and acquisitions. Additionally, Dr. Li has worked on behalf of several leading investment banking firms leveraging his industry and regional networks. Dr. Li possesses close relationships with the provincial government ecosystem throughout China, and has leveraged these networks to assist in facilitating M&A, joint ventures on behalf of his clients.
Between 2004 and 2008, Dr. Li served as Assistant Vice President at Wedbush Morgan Securities where he assisted Wedbush's private wealth management team advise clients active in the public and private equity biotechnology-related markets in China and the U.S. Previous to Wedbush, Dr. Li served with UBS Financial Services in a similar private client services advisory role.
Previous to his career advising US-based financial firms, Dr. Li held Assistant Professor and Professor positions at several medical institutions including the Pharmacology Department at the Medical College of Ohio in Toledo, the School of Biologicial Sciences at the University of Missouri-Kansas City, the Beijing Medical University in Beijing, China, and as a Physician at the Center for Disease Control for Hubei Province in Wuhan, China. Dr. Li received his Ph.D. in Pharmacology and M.D. from Beijing Medical University. Richard splits his time between Pantek's California and China offices.
Sterling leads Pantek's Media practice. Sterling as one of the leading M&A dealmakers in China media, brings over 10 years of M&A experience in the Chinese media sector. Sterling comes to Pantek after having led the M&A team for Xinhua Finance Limited (XFN) and Xinhua Sports & Entertainment Ltd. (XSEL) since 2003, one of the most prolific M&A players in China over the past decade. At Xinhua, Sterling assisted with the XFN Tokyo public listing and XSEL's listing on the Nasdaq. Following the company’s Nasdaq listing in 2007, Sterling led a successful rollup of 10 media companies in China totaling several hundred million dollars spanning print, online, radio and TV advertising and publishing via Xinhua’s in-house investment banking division, Xinhua Capital. This series of transactions represents the largest M&A rollup in the Chinese media sector for the past 50 years.
Upon successful completion of these deals at Xinhua, Sterling managed the eventual spinoff of Xinhua Capital from XSEL as an independent investment bank focused on reverse merger listings and private placements for China-based companies in media and related industries. Sterling continues to manage Xinhua Capital as a founding partner where Sterling and his team provide specialized advisory services pertaining to reverse-merger listings and private placements for China-based companies.
Prior to Xinhua, Sterling consulted on the successful launch and business development of the Santa Barbara Market Neutral Fund, a fund of funds hedge fund. During that time period Mr. LeFevre also advised on numerous private equity placements and was instrumental in the founding of The Dream Foundation.
Galen joined Pantek in 2013 and provides deal support to Pantek’s US and European clients and is based in Pantek’s San Diego offices. Galen has been involved with China since 2007 when he moved to Shanghai without speaking a word of Chinese nor knowing anyone in the country. Galen ended up living in China of over 3 years and becoming proficient in Chinese. Galen worked in the private sector in China helping U.S. and European companies invest in the country. Galen also held positions with the U.S. Department of Commerce working on U.S.- China trade development and investment policy. Galen holds a master’s degree in International Management from the University of California San Diego School of International Relations and Pacific Studies and a bachelor’s degree in Political Science from the University of Pittsburgh.
Because of the highly specialized nature of the services we provide to our clients and the costs associated with managing and executing an efficient and success-oriented cross-border platform model, we typically engage with clients on a monthly retainer basis coupled with back-end success-based milestone fees. For activities that require a registered broker-dealer, Pantek has a partnership with a registered broker-dealer and can provide broker-dealer clearance for its clients as needed via this partnership.
Pandexa International, Inc. - The principals of Pantek Partners founded Pandexa International Inc. in 2014 to provide North American food & beverage brands wishing to enter the Chinese market with economical access to high-value sophisticated market entry services, tools and trading capabilities via a turn-key import/export trade platform. More info on Pandexa can be found here: www.pandexa.com .
Cacao Bahia is a operating unit of Pantek Partners LLC and is engaged in the trading of premium agriculture commodities. Cacao Bahia currently trades premium USDA-certified organic cocoa beans sourced from Brazil and sold in the global markets under the brand name Cacao Bahia TM  .  More info can be found here: www.cacaobahia.com.
Pantek's US office is located in San Diego in Sorrento Valley, in the heart of Southern California's communications and biotechnology hubs, and home to several of the world's leading companies, universities and laboratories.